DE69728585D1 - Mittel gegen Juckreiz - Google Patents

Mittel gegen Juckreiz

Info

Publication number
DE69728585D1
DE69728585D1 DE69728585T DE69728585T DE69728585D1 DE 69728585 D1 DE69728585 D1 DE 69728585D1 DE 69728585 T DE69728585 T DE 69728585T DE 69728585 T DE69728585 T DE 69728585T DE 69728585 D1 DE69728585 D1 DE 69728585D1
Authority
DE
Germany
Prior art keywords
antipruritic agent
antipruritic
morphinian
opiate
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69728585T
Other languages
English (en)
Other versions
DE69728585T2 (de
Inventor
Hiroshi Nagase
Jun Utsumi
Takashi Endoh
Toshiaki Tanaka
Kuniaki Kawamura
Junzo Kamei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18041771&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69728585(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Application granted granted Critical
Publication of DE69728585D1 publication Critical patent/DE69728585D1/de
Publication of DE69728585T2 publication Critical patent/DE69728585T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
DE69728585T 1996-11-25 1997-11-21 Mittel gegen Juckreiz Expired - Lifetime DE69728585T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP31347696 1996-11-25
JP31347696 1996-11-25

Publications (2)

Publication Number Publication Date
DE69728585D1 true DE69728585D1 (de) 2004-05-13
DE69728585T2 DE69728585T2 (de) 2004-08-05

Family

ID=18041771

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69737592T Expired - Lifetime DE69737592T2 (de) 1996-11-25 1997-11-21 Mittel gegen juckreiz
DE69732868T Expired - Lifetime DE69732868T2 (de) 1996-11-25 1997-11-21 Mittel gegen Juckreiz
DE69728585T Expired - Lifetime DE69728585T2 (de) 1996-11-25 1997-11-21 Mittel gegen Juckreiz

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69737592T Expired - Lifetime DE69737592T2 (de) 1996-11-25 1997-11-21 Mittel gegen juckreiz
DE69732868T Expired - Lifetime DE69732868T2 (de) 1996-11-25 1997-11-21 Mittel gegen Juckreiz

Country Status (15)

Country Link
US (2) US6174891B1 (de)
EP (5) EP0897726B1 (de)
KR (1) KR100557801B1 (de)
CN (3) CN1180844C (de)
AT (3) ATE263563T1 (de)
AU (1) AU738743B2 (de)
CA (1) CA2244256C (de)
DE (3) DE69737592T2 (de)
DK (1) DK0897726T3 (de)
ES (3) ES2215158T3 (de)
NO (1) NO316309B1 (de)
NZ (1) NZ331001A (de)
PT (1) PT897726E (de)
TW (1) TW542838B (de)
WO (1) WO1998023290A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763445A (en) 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
AU1290797A (en) * 1996-12-24 1998-07-17 George F. El Khoury Topical application of opioid drugs such as morphine for relief of itching and skin disease or irritation
EP0996434A4 (de) * 1997-07-14 2001-10-10 Adolor Corp Kappa-rezeptor agonisten enthaltende antipruritische arzneimittel und verfahren zur behandlung von pruritis
JP3211027B2 (ja) * 1998-11-13 2001-09-25 丸石製薬株式会社 カプサイシン含有外用剤
WO2001014382A1 (fr) * 1999-08-23 2001-03-01 Toray Industries, Inc. Analgesiques contenant des derives sel d'ammonium quaternaire comme principe actif
CA2383146C (en) * 1999-08-24 2010-11-16 Hiroshi Nagase Therapeutic agent for neuropathic pain and neuropathic pain animal model
WO2001074819A1 (fr) * 2000-04-03 2001-10-11 Toray Industries, Inc. Agents analgesiques contenant des derives de n-oxyde de morphinane en tant que principe actif
JP2002249442A (ja) * 2001-02-21 2002-09-06 Fumakilla Ltd アレルギー減感作治療薬
CA2442423C (en) 2001-03-30 2009-11-03 Toray Industries, Inc. Therapeutic drug for psychoneurotic disorders
US7294688B2 (en) 2001-04-30 2007-11-13 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons
US6617308B2 (en) 2001-04-30 2003-09-09 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons
US7652025B2 (en) * 2001-05-08 2010-01-26 Toray Industries, Inc. Remedies for sepsis
US6844438B2 (en) * 2001-08-15 2005-01-18 Mclean Hospital Corporation N-substituted derivatives of morphinan and uses thereof
EP1450824A4 (de) * 2001-11-02 2005-09-28 Elan Corp Plc Pharmazeutische zusammensetzung
CA2480560C (en) * 2002-03-29 2011-02-15 Santen Pharmaceutical Co., Ltd. .kappa.-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative
JP5189242B2 (ja) * 2002-09-23 2013-04-24 アルケルメス ファーマ アイルランド リミテッド 乱用抵抗性の医薬組成物
CA2500118C (en) * 2002-09-25 2011-04-12 Euro-Celtique S.A. N-substituted hydromorphones and the use thereof
US7718664B2 (en) 2004-03-30 2010-05-18 Toray Industries, Inc. Anti-itching agent
US7704522B2 (en) * 2004-09-08 2010-04-27 Clyde Morgan Topical medicament
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
EP1809104A4 (de) * 2004-09-23 2009-04-29 Alexander Michalow Verfahren zum regeln von neurotransmittersystemen durch gegenadaptationen
US20060159748A1 (en) * 2004-12-23 2006-07-20 Rajesh Jain Oral immediate release formulation of a poorly water-soluble active substance
US7453122B2 (en) * 2005-02-08 2008-11-18 Taiwan Semiconductor Manufacturing Co., Ltd. SOI MOSFET device with reduced polysilicon loading on active area
US9051335B2 (en) * 2005-03-10 2015-06-09 Toray Industries, Inc. Antipruritic agent for pruritus caused by multiple sclerosis
HUE029202T2 (en) * 2005-04-06 2017-02-28 Toray Industries Crystals and procedure for the preparation of morphinane derivatives
EP1953164B1 (de) * 2005-11-09 2014-05-14 Toray Industries, Inc. Therapeutisches oder prophylaktisches mittel gegen funktionelle darmerkrankung
AU2006328765B2 (en) * 2005-12-21 2012-01-12 Toray Industries, Inc. Antitussive agent
NZ575620A (en) * 2006-09-20 2010-11-26 Mallinckrodt Inc Preparation of substituted morphinan-6-ones and salts and intermediates thereof
US9040726B2 (en) 2007-03-06 2015-05-26 Mallinckrodt Llc Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
EP2137189B1 (de) * 2007-03-06 2015-05-06 Mallinckrodt LLC Verfahren zur herstellung quaternärer n-alkyl-morphinin-alkaloid-derivate
US8796301B2 (en) 2007-04-24 2014-08-05 Toray Industries, Inc. Therapeutic or prophylactic agent for dyskinesia
JP5099127B2 (ja) 2007-04-26 2012-12-12 東レ株式会社 ４，５−エポキシモルヒナン誘導体を含有する安定な固形製剤
US8183256B2 (en) * 2007-06-22 2012-05-22 Toray Industries, Inc. Remedy or preventive for integration dysfunction syndrome
MX2010003660A (es) * 2007-10-05 2010-08-10 Toray Industries Agente para aliviar problemas de la piel que comprende un derivado de morfinano o una sal de adicion de acido, farmacologicamente aceptable del mismo como ingrediente activo.
WO2009138734A2 (en) * 2008-05-14 2009-11-19 Serentis Limited Use of opioid compounds in peripheral pain, wound healing and scar formation
ES2549904T3 (es) * 2008-05-27 2015-11-03 Mallinckrodt Llc Procesos y compuestos para la preparación de normorfinanos
US9458109B2 (en) * 2008-09-03 2016-10-04 Mallinckrodt Llc Substituted berbines and processes for their synthesis
CN102325777B (zh) * 2009-02-23 2015-08-12 马林克罗特公司 (+)-吗啡喃*n-氧化物及其制备方法
US8946419B2 (en) 2009-02-23 2015-02-03 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
WO2010096788A1 (en) * 2009-02-23 2010-08-26 Mallinckrodt Inc. (+)-morphinanium quaternary salts and processes for their production
JP2012518652A (ja) * 2009-02-23 2012-08-16 マリンクロッド インコーポレイテッド （＋）−６−ヒドロキシ−モルフィナンまたは（＋）−６−アミノ−モルフィナン誘導体
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
MY173491A (en) * 2010-01-29 2020-01-29 Toray Industries Therapeutic or prophylactic agent for biliary tract diseases
MX2013008749A (es) 2011-01-31 2013-10-17 Toray Industries Agente terapeutico o profilactico para caquexia.
CN103917543A (zh) 2011-09-08 2014-07-09 马林克罗特有限公司 在不分离中间体的情况下制备生物碱
JP6064252B2 (ja) * 2012-01-19 2017-01-25 三笠製薬株式会社 そう痒症改善経皮吸収貼付剤
EP2931279B1 (de) * 2012-12-14 2024-03-20 Trevi Therapeutics, Inc. Verfahren zur behandlung von pruritus
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
JPWO2016052617A1 (ja) * 2014-09-30 2017-09-21 国立大学法人 筑波大学 ナルフラフィン含有局所適用製剤
TW201707703A (zh) * 2015-06-04 2017-03-01 Tokai Capsule Co Ltd 軟膠囊劑
CN106866688B (zh) * 2015-12-10 2019-05-03 山东诚创医药技术开发有限公司 一种纳呋拉啡的精制方法
AU2017238051B9 (en) * 2016-03-21 2022-11-03 Trevi Therapeutics, Inc. Treatment of uremic pruritus
TW201821108A (zh) * 2016-12-06 2018-06-16 大陸商江蘇恆瑞醫藥股份有限公司 一種κ類鴉片受體激動劑在製備治療法尼醇Ｘ受體激動劑引起的瘙癢的藥物中的用途
AU2019229892A1 (en) 2018-03-08 2020-09-03 University Of Kansas Treatment of demyelinating diseases
CN112703000A (zh) 2018-07-23 2021-04-23 特雷维治疗股份有限公司 慢性咳嗽、呼吸急促和呼吸困难的治疗
CA3135344A1 (en) * 2019-03-29 2020-10-08 Nippon Chemiphar Co., Ltd. Use of t-type calcium channel blocker for treating pruritus
TW202216145A (zh) 2020-06-30 2022-05-01 日商東麗股份有限公司 伴隨代謝異常之疾病或症候群中的肌力低下症狀之改善劑或預防劑
EP4334298A1 (de) 2021-06-14 2024-03-13 Scorpion Therapeutics, Inc. Harnstoffderivate zur behandlung von krebs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU196376B (en) * 1985-05-23 1988-11-28 Sandoz Ag Process for preparing morphinane derivatives and pharmaceutical compositions containing such compounds
US5021413B1 (en) * 1988-08-24 1994-12-13 Sankyo Co Analgesic thiomorpholins, their preparation, and pharmaceutical compositions containing them
PT94070A (pt) * 1989-05-18 1991-01-08 Glaxo Group Ltd Processo para a preparacao de derivados de piperazina
ES2121988T3 (es) * 1992-01-23 1998-12-16 Toray Industries Derivado de morfinano y uso medicinal.
JPH06122677A (ja) * 1992-08-28 1994-05-06 Sankyo Co Ltd 光学活性なカルボン酸アミド誘導体
DE69413933T2 (de) * 1993-06-30 1999-04-08 Toray Industries Antitussiva
JPH09504018A (ja) * 1993-10-20 1997-04-22 ザ ブーツ カンパニー ピーエルシー 抗掻痒薬としてのイブプロフェンおよびフルルビプロフェン
IT1273751B (it) 1994-02-11 1997-07-10 Smithkline Beecham Farma Derivati azaciclici
EP0996434A4 (de) * 1997-07-14 2001-10-10 Adolor Corp Kappa-rezeptor agonisten enthaltende antipruritische arzneimittel und verfahren zur behandlung von pruritis
US5760023A (en) 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith

Also Published As

Publication number Publication date
CN1291717C (zh) 2006-12-27
CA2244256C (en) 2006-07-11
ES2285733T3 (es) 2007-11-16
EP1310251A1 (de) 2003-05-14
CN1530111A (zh) 2004-09-22
PT897726E (pt) 2007-07-09
NO983431L (no) 1998-09-24
EP1310255B1 (de) 2004-04-07
DE69737592T2 (de) 2008-01-03
DE69737592D1 (de) 2007-05-24
NZ331001A (en) 2000-05-26
DE69732868D1 (de) 2005-04-28
US6174891B1 (en) 2001-01-16
WO1998023290A1 (fr) 1998-06-04
ES2215158T3 (es) 2004-10-01
DE69732868T2 (de) 2006-04-13
EP1327444B1 (de) 2005-03-23
AU738743B2 (en) 2001-09-27
ES2236630T3 (es) 2005-07-16
CN1180844C (zh) 2004-12-22
JP3531170B2 (ja) 2004-05-24
ATE359076T1 (de) 2007-05-15
CA2244256A1 (en) 1998-06-04
KR100557801B1 (ko) 2006-04-21
EP1310255A1 (de) 2003-05-14
EP0897726A1 (de) 1999-02-24
ATE291429T1 (de) 2005-04-15
US6316461B1 (en) 2001-11-13
DE69728585T2 (de) 2004-08-05
KR19990081978A (ko) 1999-11-15
EP1327444A1 (de) 2003-07-16
ATE263563T1 (de) 2004-04-15
DK0897726T3 (da) 2007-08-13
CN1214634A (zh) 1999-04-21
EP1312361A1 (de) 2003-05-21
TW542838B (en) 2003-07-21
EP0897726B1 (de) 2007-04-11
CN1535687A (zh) 2004-10-13
AU4968397A (en) 1998-06-22
EP0897726A4 (de) 2003-05-28
NO316309B1 (no) 2004-01-12
NO983431D0 (no) 1998-07-24

Similar Documents

Publication Publication Date Title
DE69728585D1 (de) Mittel gegen Juckreiz
IL138476A0 (en) Method for treating pharmaceutical compositions by special use of anti-oxidant
AU2002213336A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
PT800519E (pt) Compostos moduladores de receptores de esteroides e metodos
PE14199A1 (es) Agonistas de 5-ht1f
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
TW200420573A (en) Bifunctional heterocyclic compounds and methods of making and using same
RS63204A (en) Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
EA200300566A1 (ru) Применение cci-779 в качестве противоопухолевого средства
ATE231872T1 (de) Thiazolopyrimidinderivate
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
ATE386742T1 (de) Imidazonaphthyridine
PT971922E (pt) Compostos de tetra-hidropirido
IL152097A0 (en) Use of pyrazole derivatives for treating infertility
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
BR0206917A (pt) Uso de antagonistas de mglur5 para o tratamento de condições prurìticas
NO20002408D0 (no) 5-HT1F antagonister
NO20005548D0 (no) Mykobakterieinhibitorer
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
EA199800858A1 (ru) Способ лечения насморка или аллергического ринита
BR0214244A (pt) Uso de uma ascomicina
EA200001105A1 (ru) 10-камфорсульфонат пароксетина для лечения нарушений цнс

Legal Events

Date Code Title Description
8364 No opposition during term of opposition